Glycogen storage disease due to liver phosphorylase kinase deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:264580OMIM:306000E74.0
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Glycogen storage disease due to liver phosphorylase kinase deficiency (also known as GSD type IX, or PhK deficiency of the liver) is a group of inherited metabolic disorders in which the enzyme phosphorylase kinase is deficient or dysfunctional in the liver. Phosphorylase kinase plays a critical role in glycogen breakdown (glycogenolysis) by activating glycogen phosphorylase. When this enzyme is deficient, glycogen accumulates abnormally in the liver, leading to hepatomegaly (enlarged liver), growth retardation, and elevated liver transaminases. Affected children typically present in early childhood with a protuberant abdomen due to hepatomegaly, short stature, fasting hypoglycemia, and hyperlipidemia. Fasting ketosis may also occur. The condition is generally considered one of the milder glycogen storage diseases, and symptoms often improve with age, with many patients experiencing resolution of hepatomegaly and normalization of growth by adulthood. The most common form of liver phosphorylase kinase deficiency is X-linked (GSD IXa), caused by mutations in the PHKA2 gene, which encodes the liver-specific alpha subunit of phosphorylase kinase. Less common autosomal recessive forms exist, caused by mutations in the PHKB gene (encoding the beta subunit, GSD IXb) or the PHKG2 gene (encoding the liver-specific gamma subunit, GSD IXc). The PHKG2-related form tends to be more severe and may progress to liver fibrosis or cirrhosis in some cases. Diagnosis is based on clinical findings, biochemical testing (including enzyme activity assays in liver tissue or blood cells), and molecular genetic testing. Treatment is primarily supportive and dietary. Frequent meals rich in complex carbohydrates, avoidance of prolonged fasting, and in some cases cornstarch supplementation are used to maintain blood glucose levels and support normal growth. Protein supplementation may also be beneficial. Prognosis is generally favorable, particularly for the X-linked form, with most patients leading normal lives in adulthood. Regular monitoring of liver function and growth is recommended throughout childhood.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal erythrocyte enzyme concentration or activityHP:0030272KetosisHP:0001946Fasting hypoglycemiaHP:0003162HyperketonemiaHP:0410175Irregular menstruationHP:0000858
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Glycogen storage disease due to liver phosphorylase kinase deficiency.

View clinical trials →

No actively recruiting trials found for Glycogen storage disease due to liver phosphorylase kinase deficiency at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Glycogen storage disease due to liver phosphorylase kinase deficiency community →

No specialists are currently listed for Glycogen storage disease due to liver phosphorylase kinase deficiency.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Glycogen storage disease due to liver phosphorylase kinase deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Glycogen storage disease due to liver phosphorylase kinase deficiencyForum →

No community posts yet. Be the first to share your experience with Glycogen storage disease due to liver phosphorylase kinase deficiency.

Start the conversation →

Latest news about Glycogen storage disease due to liver phosphorylase kinase deficiency

No recent news articles for Glycogen storage disease due to liver phosphorylase kinase deficiency.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Glycogen storage disease due to liver phosphorylase kinase deficiency

What is Glycogen storage disease due to liver phosphorylase kinase deficiency?

Glycogen storage disease due to liver phosphorylase kinase deficiency (also known as GSD type IX, or PhK deficiency of the liver) is a group of inherited metabolic disorders in which the enzyme phosphorylase kinase is deficient or dysfunctional in the liver. Phosphorylase kinase plays a critical role in glycogen breakdown (glycogenolysis) by activating glycogen phosphorylase. When this enzyme is deficient, glycogen accumulates abnormally in the liver, leading to hepatomegaly (enlarged liver), growth retardation, and elevated liver transaminases. Affected children typically present in early chi

At what age does Glycogen storage disease due to liver phosphorylase kinase deficiency typically begin?

Typical onset of Glycogen storage disease due to liver phosphorylase kinase deficiency is childhood. Age of onset can vary across affected individuals.